Novartis raised its full-year core operating income guidance after third-quarter results.
Novartis raised its full-year core operating income guidance following strong third-quarter demand for its key cancer and multiple sclerosis drugs. The company's profit was affected by drug-trial setbacks.
14
Divergence score
2 outlets covered it, splitting into 2 framing camps across 2 bias groups.
2 camps
2 bias groups
Market signalBETA
The spectrum · how 2 outlets placed this story
LeftCenterRight
Wall Street Journal
Reuters
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
Widest split · the two outlets furthest apart, and who published first
Furthest apart on this story
Wall Street Journal
Novartis Raises Guidance Despite Drug-Trial Setbacks Hitting Profit - WSJ
guidance raise offset by trial setbacks · neutral
Reuters
Novartis raises full year core operating income guidance
guidance raise on strong drug demand · positive
First to report
- Reutersfirst
- Wall Street Journal+16.1 h
By each outlet's earliest publish time in this story. Feeds that index slowly can appear later than they printed.
The split, in one line
Both report the guidance raise; one leads with strong cancer and MS drug demand, the other with drug-trial setbacks hitting profit.
How each outlet covered it
Lightly covered so far
Too few outlets to map a left-right split. Here is each take as it stands.
Sparse coverage · 2 outlets
“Novartis raises full year core operating income guidance”
“Novartis Raises Guidance Despite Drug-Trial Setbacks Hitting Profit - WSJ”
3 tracked claims across 2 outlets
Fact ledger
All3Claimed2Corroborated1
1/2
Claimed
Strong third-quarter demand for key cancer and multiple sclerosis drugs drove the results
Corroborated
Disputed
2 more tracked claimsSign up free to see the full ledger